CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Diagnovus, a molecular diagnostics company focused on underserved, aggressive, and lesser-known diseases, announced the launch of the Engauge GI Barrett’s Esophagus genomic assay to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in Barrett’s esophagus patients.
Engauge GI Barrett’s Esophagus is a proprietary gene-expression assay that uses RT-PCR to determine the methylation profile of a panel of eight genes. An important addition to Diagnovus’ Engauge product portfolio, the assay uses biopsy material taken during endoscopic surveillance and can be performed in a highly reproducible and accurate manner using formalin-fixed, paraffin-embedded diagnostic biopsy tissue. All samples are analyzed at Diagnovus’ high-complexity, CLIA-certified laboratory.
“At Diagnovus, our goal in launching the Engauge GI Barrett’s Esophagus assay is to provide physicians with a unique and adjunctive assessment of a Barrett’s esophagus patient’s risk of progressing,” James Stover, PhD, vice president and cofounder of Diagnovus, said in a statement. “With this addition to their current standard of care, physicians now have the ability to better identify progressor and nonprogressor patients and then tailor surveillance frequency specific to each patient.”
Diagnovus, 855-642-8438